Neutropenia News and Research RSS Feed - Neutropenia News and Research

Neutropenia is a hematological disorder characterized by an abnormally low number of neutrophils, the most important type of white blood cell, in the blood.
FDA approves new therapy for initial treatment of soft tissue sarcoma

FDA approves new therapy for initial treatment of soft tissue sarcoma

The U.S. Food and Drug Administration today granted accelerated approval to Lartruvo (olaratumab) with doxorubicin to treat adults with certain types of soft tissue sarcoma (STS), which are cancers that develop in muscles, fat, tendons or other soft tissues. [More]
Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

Long-term clinical data, experience supports effectiveness of PRRT for treating neuroendocrine tumors

More than ten years of published clinical data and personal experience using PRRT-based targeted therapy of neuroendocrine tumors supports the effectiveness of this novel treatment approach and the ability to minimize and manage potential toxic side effects. [More]
Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

Combination treatment with CDK4/6 inhibitor improves progression-free survival in HR+ breast cancer patients

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen. [More]
Managing low-risk acute care without hospitalization appears to be safe and reduces costs

Managing low-risk acute care without hospitalization appears to be safe and reduces costs

A comprehensive review of studies evaluating strategies for treating certain acute medical conditions without hospital admission finds that all four evaluated strategies appear to be safe, often improve patient and caregiver satisfaction, and reduce health care costs. [More]
Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen seeks to extend DARZALEX license to benefit more multiple myeloma patients

Janssen-Cilag International NV has announced the submission of a Type II variation application to the European Medicines Agency (EMA), seeking to broaden the existing marketing authorisation for the immunotherapy DARZALEX® (daratumumab) to include treatment of adult patients with relapsed multiple myeloma who have received at least one prior therapy. The expanded indication is based on daratumumab in combination with lenalidomide (an immmunomodulatory agent) and dexamethasone, or bortezomib (a PI) and dexamethasone. [More]
BCL-2 inhibitor shows promise in AML patients

BCL-2 inhibitor shows promise in AML patients

Patients whose acute myelogenous leukemia (AML) had relapsed or was resistant to chemotherapy and those who were deemed unable to tolerate chemotherapy experienced responses to the selective BCL-2 inhibitor venetoclax (Venclexta), with complete remissions in some, according to phase II clinical trial data. [More]
Researchers identify specific pathways involved in development of mucormycosis

Researchers identify specific pathways involved in development of mucormycosis

Research published today in the journal, Nature Communications, provides new insights into the evolution of Mucorales fungi, which cause a fatal infection in ever-increasing segments of patient population, and several molecular pathways that might be exploited as potential therapeutic or diagnostic targets. [More]
Clinical trial to evaluate safety of palbociclib drug in African American women with breast cancer

Clinical trial to evaluate safety of palbociclib drug in African American women with breast cancer

The first clinical trial to test a newly approved breast cancer drug specifically in African American patients is now enrolling at Georgetown Lombardi Comprehensive Cancer Center and will begin soon at five other institutions in Washington, DC, Maryland, Alabama and New Jersey. [More]
European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

European Commission approves extended indication for Amgen's Kyprolis (carfilzomib) for the treatment of relapsed multiple myeloma patients

Amgen has announced that the European Commission (EC) has approved a variation to the marketing authorization for Kyprolis® (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy. The extended indication marks the second approval for Kyprolis by the EC in less than a year. [More]
Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

Everolimus combined with standard R-CHOP therapy shows promise in treating DLBCL patients

The targeted therapy everolimus may be safely combined with R-CHOP for new, untreated diffuse large B-cell lymphoma according to the results of a pilot study by Mayo Clinic researchers published in the Lancet Haematology. [More]
New IDSA guidelines focus on diagnosis, treatment of deadly aspergillosis

New IDSA guidelines focus on diagnosis, treatment of deadly aspergillosis

New therapies are improving care, but early diagnosis remains critical in the effective treatment of invasive, a potentially deadly fungal infection, according to new guidelines released by the Infectious Diseases Society of America and published in the journal Clinical Infectious Diseases. [More]
Salvage inotuzumab ozogamicin improves ALL outcomes

Salvage inotuzumab ozogamicin improves ALL outcomes

Compared with standard chemotherapy, treatment with inotuzumab ozogamicin increases the rate of complete remission and allows a higher proportion of patients with relapsed or refractory acute lymphoblastic leukaemia to subsequently receive stem-cell transplantation, research suggests. [More]
Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

Final DASISION study findings confirm dasatinib to be an effective, long-term treatment for patients with a new diagnosis of chronic phase-chronic myeloid leukaemia. [More]
New drug ixekizumab helps clear severe psoriasis symptoms

New drug ixekizumab helps clear severe psoriasis symptoms

About 80 percent of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab, according to three large, long-term clinical trials led by Northwestern Medicine. [More]
Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago. [More]
Combination therapy equally good at treating small cell lung cancer

Combination therapy equally good at treating small cell lung cancer

HAVING radiotherapy once a day for six and a half weeks or twice a day for three weeks -- when combined with chemotherapy -- is equally good at treating small cell lung cancer that hasn't spread. [More]
EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

EPIC Results Shed Light On First-Line Ponatinib Risk-Benefit Profile

The primary endpoint of major molecular response at 12 months for ponatinib versus imatinib in patients with newly diagnosed chronic phase-chronic myeloid leukaemia remains undetermined, report the EPIC trial investigators. [More]
Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]
Rare germ cell tumor creates unique bond between two young women

Rare germ cell tumor creates unique bond between two young women

Morgan Ellison and Madison McDaniel were diagnosed with a rare germ cell tumor of the ovary earlier this year. The two strangers would soon form a unique bond during their treatment in Birmingham, Alabama. [More]
Advertisement
Advertisement